Skip to main content
. Author manuscript; available in PMC: 2015 Apr 20.
Published in final edited form as: J Urol. 2014 Oct 31;193(4):1388–1393. doi: 10.1016/j.juro.2014.10.101

Fig. 2.

Fig. 2

Survival of castrated mice bearing LNCaP xenograft tumors. A. Kaplan–Meier Survival Curve of castrated mice (C), castrated mice treated with multiple cycles of short testosterone-induced off-cycles (C+T) and with dutasteride (C+T+D). Number of mice in each treatment group given in parentheses, *, p < 0.05 when comparing C+T+D to C or C+T by Mantel-Cox log-rank test, p> 0.05 when comparing C to C+T. B. Median survival of mice in group C was 35 days (95% confidence interval [CI], 28–44), 37 days in group C+T (95% CI, 29–44), and 46 days in group C+T+D (95% CI, 39–52), p value for indicated comparisons by Student’s t-test. C. Survival of mice bearing tumors at the end of each off-cycle. Groups include castrated mice (C), castrated mice treated with multiple cycles of short testosterone-induced off-cycles (C+T) with dutasteride (C+T+D).